CMC Biologics has completed a new disposable manufacturing facility at its Seattle, WA site. The addition is part of a major expansion to add production capacity to its existing facility for the cGMP manufacture of biopharmaceuticals. The multi-purpose, single-use facility will allow for early-phase clinical manufacture of biopharmaceuticals including monoclonal antibodies and other mammalian cell culture-based recombinant proteins. CMC has partnered with Hyclone to supply the new disposable ...